Geron Corp

GERN is in a Stage 2 advance with a bullish medium-term bias confirmed by a Momentum Breakout and higher highs/lows. Yet price is now extreme overbought and extended well above the rising EMAs, so execution is deferred until shallow pullbacks into the 9/20/50 EMA support zone.

• ↑Q1 net revenue $51.8M (31% YoY), on track for $220–240M guidance
• ↑$341M cash position supports R&D spend and market expansion
• ↓Projected 2026 operating expenses of $230–240M accelerate cash burn